FDA approves treatment for T-cell lymphoma after strong results in clinical trial
WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a supplemental biologics license application for Eisai’s lymphoma drug Ontak, Eisai said Wednesday.
The drug, known generically as denileukin diftitox, is an injection for treating persistent or recurrent cutaneous T-cell lymphoma.
The FDA’s action was based on a phase 3 clinical trial that evaluated the safety and efficacy of Ontak in certain patients with CTCL, which refers to a group of rare, malignant lymphomas that occur primarily in the skin. Eisai said the trial was the largest randomized, double-blind and placebo-controlled phase III study ever conducted on the disease.
“These data confirm the benefit of the safety and efficacy profiles of Ontak,” Yale Cancer Center professor of medicine, Francine Foss, said.
Medicare patients not getting cancer screenings often enough
ROCKVILLE, Md. A study by researchers at the University of North Carolina shows that screening rates for certain types of cancer among older Medicaid patients lag behind national objectives.
The study, published in the Oct. 13 issue of the Archives of Internal Medicine and based on documented evidence, analyzed 1,951 Medicaid recipients in North Carolina aged 50 and older and found that physicians recommended screening for colorectal, breast and cervical cancer to 52.7 percent, 60.4 percent and 51.5 percent of patients, respectively.
Respective rates of adequate screening for the three cancers were 28.2 percent, 31.7 percent and 31.6 percent.
Report shows Philadelphia has high rate of those treated for diabetes type 2
PHILADELPHIA Percentages of people in Philadelphia who receive services to treat type 2 diabetes are higher than national averages. At the same time, the percentage of working-age people with the disease is higher in the city than the national average.
These are some of the results in the Greater Philadelphia Type 2 Diabetes Report for 2008, released Wednesday by the Greater Philadelphia Diabetes Coalition, which analyzed the demographics, costs and quality of care for people in the city with type 2 diabetes. The report included data from around the city’s metropolitan area, as well as western Pennsylvania and Atlantic City, N.J.
“GPDC helped develop the Greater Philadelphia Type 2 Diabetes Report to serve as a useful resource for employers, illustrating the seirous negative impact diabetes has on the Greater Philadelphia area,” GPDC chairman Dr. Ronald Brooks said. “This report points out the need to prevent diabetes through exercise and prudent nutrition as well as the importance that people with diabetes receive optimal care, based on evidence-based guidelines.”
The report also shows that 57 percent of Philadelphia residents in 2007 were between 18 and 64 years old, higher than the national average of 52.3 percent. In Atlantic City, the rate was 59.4 percent.
It also shows that costs for care of people with Type 2 diabetes are higher in Philadelphia than in the other five markets profiled. In 2007, the average hospital inpatient charges for treating Type 2 diabetics was $95,813, almost twice as high as the national average of $49,870. Hospital outpatient charges were $6,168, while the national average was $4,673.